Skip to main content
. 2012 Jul 18;7(7):e40400. doi: 10.1371/journal.pone.0040400

Figure 4. Body mass [g] of 14-day-old males (wild type (wt) or mosaic mutants (ms/−)) from untreated, CuCl2- or CuCl2-DMDTC-treated heterozygous mothers (ms/+); (a) Significantly different from untreated control wild-type males P<0.05; (b) Significantly different from CuCl2-treated wild-type males P<0.01; (c) Significantly different from untreated control wild-type males P<0.0000; (d) Significantly different from CuCl2-treated wild-type males P<0.001; (e) Significantly different from untreated mosaic males P<0.05; (f) Significantly different from CuCl2-DMDTC-treated wild-type males P<0.0000; (g) Significantly different from untreated mosaic males P<0.05.

Figure 4

There is no difference between prenatal CuCl2-treated and prenatal CuCl2-DMDTC treated mosaic males. The number of mice in each group is shown in brackets.